Breaking News
1. India to rebuild canals, dig new ones to tap into Indus      2. Russia, Ukraine agree to swap prisoners, fail to reach truce      3. "India Has Launched Missiles": Pak PM Shehbaz Sharif Recounts 2:30 AM Asim Munir Call      4. Mumbai airport picks Indo Thai as interim ground handler after Turkish firm Celebi’s exit      5. 7 MPs To Carry Anti-Terror Message To World, Shashi Tharoor Gets Key Role      6. Erdogan's daughter not owner, we are not Turkish: Aviation firm on losing clearance      7. US military strategist slams Trump admin for not blocking IMF aid to Pakistan      8. In A First, S Jaishankar Speaks To Taliban Foreign Minister, Scripts History      9. Trump once again claims he 'helped settle' India-Pak tensions; repeats US used trade as leverage      10. India-Pakistan ceasefire LIVE: Pakistan PM Shehbaz offers dialogue with India for ‘peace’      11. Indian team to present in U.N. evidence on Pahalgam terror attack      12. ‘Disparaging, dangerous’: HC orders FIR against BJP minister Vijay Shah for remarks on Col Sofiya Qureshi      13. First time, Pakistan says willing to discuss Indus Waters Treaty terms      14. Huge cache of weapons, ammunition seized in J&K's Shopian; linked to terrorists killed in Operation Keller      15. Tamil Nadu Court Sentences All Nine Accused In Pollachi Sexual Assault Case To Life Imprisonment      16. U.S. agrees to sell Saudi Arabia $142 billion arms package      17. Finally, India makes it official: Trump didn't broker India-Pakistan ceasefire      18. Donald Trump again boasts he brought peace between India, Pakistan: ‘Used trade to a large extent’      19. PM Modi visits Adampur Airbase, interacts with Air warriors, salutes their courage      20. 'Trump's revelations upstaged PM's address': Congress demands answers on US claims     

Breakthrough Chikungunya Vaccine Approved by USFDA, Offers Vital Protection Against Global Threat

In a significant stride in global healthcare, the US Food and Drug Administration (USFDA) has granted approval to Ixchiq, marking the world's first-ever vaccine designed to prevent chikungunya virus-related diseases. Tailored for individuals aged 18 and above with heightened susceptibility to chikungunya exposure, Ixchiq stands as a crucial response to the escalating threat posed by this virus.

Breakthrough Chikungunya Vaccine Approved by USFDA, Offers Vital Protection Against Global Threat Image Source -www.hindi.news24online.com

Chikungunya, a mosquito-borne virus, has burgeoned into a global health concern, with over 5 million reported cases in the past 15 years. While traditionally associated with tropical regions in Africa, Southeast Asia, and the Americas, its geographical reach has expanded, amplifying the prevalence of the disease worldwide.

Common symptoms of chikungunya encompass fever, joint pain, rash, headache, and muscle pain. In severe cases, the joint pain can persist for months or even years, particularly affecting older adults and those with underlying health conditions.

Dr. Peter Marks, Director of the FDA's Center for Biologics Evaluation and Research, emphasized the vaccine's approval as a crucial step in addressing an unmet medical need and providing a vital tool against a potentially debilitating disease.

Ixchiq, administered as a single muscle injection, contains a weakened form of the live chikungunya virus. Clinical studies in North America involving over 3,500 participants demonstrated the vaccine's safety, with common side effects being headache, fatigue, muscle and joint pain, fever, nausea, and injection site tenderness.

Despite rare severe reactions reported in 1.6% of Ixchiq recipients, the benefits of the vaccine outweigh the potential risks. The FDA mandates a postmarketing study to further assess these risks.

Transmission of the chikungunya virus to newborns has been documented, making Ixchiq's approval a significant development in safeguarding vulnerable populations. While the vaccine virus was detected in the blood shortly after vaccination, its impact on pregnant individuals and newborns remains uncertain.

Also Read: Tragic Loss In The Music World: South Korean Singer Nahee's Sudden Demise Stuns The Music Community

Ixchiq's approval comes under the Accelerated Approval pathway, reflecting the urgency in addressing the serious and life-threatening nature of chikungunya. Fast Track and Breakthrough Therapy designations, along with Priority Review, underscore the vaccine's significance in combating this global health menace.

Valneva Austria GmbH, the manufacturer, received a tropical disease priority review voucher as an incentive for advancing medical solutions targeting certain tropical diseases. This monumental approval represents a paradigm shift in combating chikungunya, offering hope and protection on a global scale. 

Author
No Image
Author
Arijit Dutta

You May Also Like